Oncology

Latest News

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com
RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

David Nguyen, MD | Image Credit: Tufts Medicine
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

July 23rd 2025

G
In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

July 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 29th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 29th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Screenshot of Sancy Leachman, MD, PhD, smiling
May 22nd 2023

Education Can Help Address Racial Disparities in Skin Cancer Diagnosis, Treatment, Says Dr Sancy Leachman

Laura Joszt, MA
Addressing racial disparities in skin cancer involves education, understanding rates of risk and ethnicity, and knowledge of the different types of melanoma, which makes skin cancer disparities complex to attack, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Flatiron Health
May 2nd 2023

Sanofi, Flatiron to Collaborate on Clinical Trial Data Acquisition at Point of Care

AJMC Staff
The partnership will help develop standards for data transfer to eliminate manual steps used in clinical trials.
TPG, AmerisourceBergen Acquire OneOncology in Deal Valued at $2.1 Billion
April 20th 2023

TPG, AmerisourceBergen Acquire OneOncology in Deal Valued at $2.1 Billion

Mary Caffrey
Under the transaction, TPG, an asset management firm, will acquire a majority interest in OneOncology and AmerisourceBergen will have a minority interest; OneOncology physician leaders and practices will retain minority interests as well.
Clinical Updates: Spring 2023
April 19th 2023

Clinical Updates: Spring 2023

AJMC Staff
Results for ribociclib, ponatinib, brexucabtagene autoleucel, and allo-HCT.
Managed Care Updates: Spring 2023
April 19th 2023

Managed Care Updates: Spring 2023

Coverage From the 2023 COA Community Oncology Conference
April 18th 2023

Coverage From the 2023 COA Community Oncology Conference

Mary Caffrey
The Community Oncology Alliance celebrated its 20th year at the Community Oncology Conference held March 23-24, 2023, in Kissimmee, Florida.
EBO logo
April 18th 2023

Coverage From ACCC 2023 Spring Business Summit

Rose McNulty
Coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit.
IVBM logo
April 18th 2023

Oncology Stakeholders Must Align in the Pursuit of Health Equity, Value-Based Care

Matthew Gavidia
Coverage from the session of the Institute for Value-Based Medicine®, held in New York, New York, on February 8, 2023. The American Journal of Managed Care® presented the event in partnership with New York Cancer and Blood Specialists.
TailorMed’s Manners: Addressing Financial Concerns in Cancer Care Improves Overall Patient Experience
April 17th 2023

TailorMed’s Manners: Addressing Financial Concerns in Cancer Care Improves Overall Patient Experience

Interview by Mary Caffrey
Evidence-Based Oncology™ (EBO) spoke with TailorMed's Ian Manners about the financial assistance and consumer protection landscape, and what the cost of cancer care means to patient experience and outcomes.
Screenshot of Sancy Leachman, MD, PhD
April 16th 2023

Dr Sancy Leachman Discusses Tailoring Genetic Testing for Melanoma to the Patient

Laura Joszt, MA
Each patient needs to weigh the benefits and risks of genetic testing for melanoma and have someone who can take the time to explain everything, including insurance risks, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Sashi Naidu, MD, Carolina Blood and Cancer Care Associates
April 9th 2023

Dr Sashi Naidu: Financial Concerns Are a Constant Challenge in Community Oncology

Maggie L. Shaw
Sashi Naidu, MD, is director of research at Carolina Blood and Cancer Care Associates, where the No One Left Alone (NOLA) initiative is working to break down cancer health disparities among its patients and prevent care fragmentation.
Dr. Lalan Wilfong
April 7th 2023

Dr Lalan Wilfong Discusses the Benefits of Value-Based Oncology

Justina Petrullo
In a value-based cancer care model, patients can more easily access the best quality care and practices can get adequately paid for the services they offer.
Dr. Ryan Huey
April 7th 2023

Dr Ryan Huey Discusses the Necessity of Teamwork in Value-Based Oncology

Justina Petrullo
Ryan Huey, MD, gastrointestinal medical oncologist at MD Anderson Cancer Center in Houston, Texas, discussed the vital roles multiple health care providers play in improving outcomes for patients with cancer.
David A. Eagle, MD, New York Cancer & Blood Specialists
April 2nd 2023

Dr David Eagle: Health Equity Involves More Than Medical Care

Maggie L. Shaw
Close to 80% of what influences how long someone is going to live is where and how they live, and we need to pay more attention to that or we’re not paying attention to everything that affects their lives, explained David A. Eagle, MD, of New York Cancer & Blood Specialists.
Screenshot of Sancy Leachman, MD, PhD, smiling
March 30th 2023

Dr Sancy Leachman Outlines a “Spectrum of Problems” Between Melanoma Detection and Treatment

Laura Joszt, MA
There is a “spectrum” of problems and obstacles in a patient’s way once melanoma has been detected before that patient sees the right physician and receives treatment, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Pembrolizumab Receives Full Approval for Select Patients With MSI-H or dMMR Solid Tumors
March 29th 2023

Pembrolizumab Receives Full Approval for Select Patients With MSI-H or dMMR Solid Tumors

Kristi Rosa
The FDA has granted full approval to pembrolizumab for the treatment of some patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors that have progressed following previous treatment.
What We’re Reading: FDA Proposes A More Thorough Approval Process; Cigna Under Claims Investigation; US Bishops Seek to Restrict Trans Care
March 27th 2023

What We’re Reading: FDA Eyes Cancer Drug Process; Cigna Claims Review Criticized; US Bishops and Trans Care

AJMC Staff
The FDA wants to discourage the use of single-arm trials for accelerated approvals of oncology drugs; Cigna’s review system allows doctors to reject claims without reading them, an investigation shows; US bishops want to restrict gender transition care in Catholic hospitals.
Samyukta Mullangi, MD, MBA.
March 25th 2023

Dr Samyukta Mullangi: Cancer Care Navigation Platforms Can Reduce Operational, Financial Challenges of VBC Systems

Matthew Gavidia
Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, discussed how the transition to value-based care can contribute to operational and financial risks among oncology practices, and the effectiveness of care navigation platforms in addressing these concerns.
Manmeet Ahluwalia, MD, MBA.
March 23rd 2023

Dr Manmeet Ahluwalia: Miami Cancer Institute Aiming to Improve Minority Enrollment in Clinical Trials by 50%

Matthew Gavidia
Manmeet Ahluwalia, MD, MBA, chief, Solid Tumor Medical Oncology; deputy director; and chief scientific officer at Miami Cancer Institute, spoke on the short- and long-term goals for Miami Cancer Institute’s Center for Equity in Cancer Care & Research in improving minority patient enrollment in clinical trials.
Nicolas Ferreyros, BA, managing director, The Community Oncology Alliance
March 22nd 2023

Nicolas Ferreyros: There Is Growing Recognition the 340B Program Is "Out of Control"

Pearl Steinzor
Growing bipartisan awareness of issues with the 340B drug pricing program will hopefully lead to reform, says Nicolas Ferreyros, BA, managing director of policy, advocacy, and communications at the Community Oncology Alliance.
Susan Sabo-Wagner, MSN, RN, OCN, Oncology Consultants
March 22nd 2023

There Is Something for Everyone to Do to Improve Health Equity, Says Oncology Consultants’ Wagner

Maggie L. Shaw
Many people believe health equity is such a big issue that there is not much an individual practice can do to address it, explained Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy, Oncology Consultants of Houston.
Osimertinib Demonstrates Overall Survival Benefit as Adjuvant Lung Cancer Treatment
March 19th 2023

Osimertinib Demonstrates Overall Survival Benefit as Adjuvant Lung Cancer Treatment

Aislinn Antrim
Osimertinib (Tagrisso; AstraZeneca) now has shown a statistically significant and clinically meaningful overall survival benefit in both the early adjuvant and late-stage metastatic settings.
Samyukta Mullangi, MD, MBA.
March 17th 2023

Dr Samyukta Mullangi: Thyme Care Provides Cancer Navigation Services at Scale With Aligned VBC Incentives

Matthew Gavidia
Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, explained Thyme Care’s value-based care (VBC) system in oncology and the benefits of care navigation.
Site Logo
March 16th 2023

Health Care Resource Utilization, Quality Metrics, and Costs of Bladder Cancer Within the Oncology Care Model

Heidi S. Wirtz, PharmD, PhD Zsolt Hepp, PharmD, MSc Simrun Grewal, PhD Phoebe Wright, PharmD, MSc Rupali Fuldeore, MSc Samantha Tomicki, MPH Jared Hirsch, MSc Gabriela Dieguez, MSc L. Johnetta Blakely, MD
Spending on novel therapies in high-risk bladder cancer had minimal impact on Oncology Care Model payments to practices, according to this cohort study and an average performance estimation.
Manmeet Ahluwalia, MD, MBA.
March 12th 2023

Dr Manmeet Ahluwalia on Improving Genomic Testing Disparities in Oncology

Matthew Gavidia
Manmeet Ahluwalia, MD, MBA, chief, Solid Tumor Medical Oncology; deputy director; and chief scientific officer at Miami Cancer Institute, addressed disparities in genomic testing among minority patients with cancer, as well as equitable care strategies at his organization’s Center for Equity in Cancer Care & Research.
Stops and Starts Abound in the Oncology Payment Landscape
March 10th 2023

Stops and Starts Abound in the Oncology Payment Landscape

Rose McNulty
A session at the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and payment, from the Cures 2.0 Act to 340B drug reimbursement.
Jeff Hunnicutt, CEO, Highlands Oncology Group
March 10th 2023

Highlands Oncology Group’s Jeff Hunnicutt Discusses Risk Under the EOM

Maggie L. Shaw
Jeff Hunnicutt, CEO of Highlands Oncology Group, explains the 2 risk options provided under the Enhancing Oncology Model (EOM) and why the mandatory downside risk might give pause to practices that saw some success in the Oncology Care Model.
Sigrun Hallmeyer, MD, Advocate Health
March 10th 2023

Dr Sigrun Hallmeyer Discusses Use of Precision Medicine in the First-line Setting

Maggie L. Shaw
As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
Kevin Davies, PhD, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
March 9th 2023

Dr Kevin Davies: There Is Great Potential for CRISPR in Genetic Diseases and Cancers

Maggie L. Shaw
Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.
Multicancer Early Detection May Change the Screening Game—If We Learn From the Past
March 9th 2023

Multicancer Early Detection May Change the Screening Game—If We Learn From the Past

Rose McNulty
A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care setting.
<1
...
101112131415161718
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo